Sugi Predict

Sugi Predict / Compounds / SCHEMBL1425929

SCHEMBL1425929

SCHEMBL1425929

CS(=O)(=O)OC1CCCN(C(=O)O)CC1

nearest known ligand 0.34

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 1/20 0.34
▸ GPR119 Q8TDV5 1/20 0.33
▸ CA1 P00915 1/20 0.32
▸ CA2 P00918 1/20 0.32
▸ TP53 P04637 2/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ KDM4E B2RXH2 2/20 0.31
▸ POLB P06746 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ DPP4 P27487 1/20 0.31
▸ DPP7 Q9UHL4 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.30
▸ TSHR P16473 1/20 0.30
▸ CYP2D6 P10635 1/20 0.30
▸ HCRTR2 O43614 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18825094 1.00 HRH3 (0.34) HRH3GPR119CA1CA2TP53
SCHEMBL559976 0.93 HRH3 (0.34) HRH3GPR119TP53TDP1KDM4E
SCHEMBL5120488 0.87 TAAR1 (0.34) CA1CA2KDM4EPOLBGAA
SCHEMBL642149 0.87 TAAR1 (0.34) CA1CA2KDM4EPOLBGAA
SCHEMBL4744840 0.87 TAAR1 (0.34) CA1CA2KDM4EPOLBGAA
SCHEMBL14705036 0.85 HRH3 (0.33) HRH3GPR119CA1CA2
SCHEMBL5667133 0.84 TAAR1 (0.36) HRH3POLBGAAMAPK1ALDH1A1
SCHEMBL2679564 0.83 TP53 (0.32) HRH3GPR119TP53TDP1
SCHEMBL344785 0.83 TP53 (0.32) HRH3GPR119TP53TDP1
SCHEMBL1998545 0.83 TP53 (0.32) HRH3GPR119TP53TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11981667-B2 Sulfonamide carboxamide compounds INFLAZOME LIMITED (IE) 2024-05-14 — — US disclosed
US-11958837-B2 Quinazolinones as PARP14 inhibitors RIBON THERAPEUTICS, INC. (US) 2024-04-16 — — US disclosed
EP-4212515-A1 QUINAZOLINONES AS PARP14 INHIBITORS Ribon Therapeutics Inc. (US) 2023-07-19 — — EP disclosed
CN-111433208-B Pyrrolo (pyrazolo) pyrimidine derivatives as LRRK2 inhibitors 奥斯考泰克公司 2023-06-30 — — CN disclosed
US-20230037255-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LTD (IE) 2023-02-02 — — US disclosed
EP-3728207-B1 QUINAZOLINONES AS PARP14 INHIBITORS RIBON THERAPEUTICS INC (US) 2023-02-01 — — EP disclosed
US-20230018702-A1 QUINAZOLINONES AS PARP14 INHIBITORS ABBVIE BIOTECHNOLOGY LTD (BM) 2023-01-19 — — US disclosed
EP-3661925-B1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LTD (IE) 2021-11-24 — — EP disclosed
US-11008308-B2 Quinazolinones as PARP14 inhibitors Ribon Therapeutics Inc. (US) 2021-05-18 — — US disclosed
EP-3096751-B1 12-EPI-PLEUROMUTILINS Nabriva Therapeutics GmbH (AT) 2021-01-06 — — EP disclosed
US-9701628-B2 12-epi pleuromutilins NABRIVA THERAPEUTICS AG (AT) 2017-07-11 — — US disclosed
EP-3096751-A1 12-EPI-PLEUROMUTILINS Nabriva Therapeutics AG (AT) 2016-11-30 — — EP disclosed
US-20160332963-A1 12-EPI PLEUROMUTILINS Nabriva Therapeutics GmbH (AT) 2016-11-17 — — US disclosed
WO-2015110481-A1 12-EPI-PLEUROMUTILINS NABRIVA THERAPEUTICS AG (AT) 2015-07-30 — — WO disclosed
US-8481524-B2 c-MET protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-07-09 — — US disclosed
US-20110136789-A1 C-MET PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-06-09 — — US disclosed
EP-2205589-B1 C-MET PROTEIN KINASE INHIBITORS VERTEX PHARMA (US) 2011-03-23 — — EP disclosed
EP-1924572-B1 REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES SMITHKLINE BEECHAM CORP (US) 2009-12-30 — — EP disclosed
EP-1963304-A1 ISOQUINOLINE DERIVATIVES N.V. Organon (NL) 2008-09-03 — — EP disclosed
WO-2007065916-A1 ISOQUINOLINE DERIVATIVES N.V. ORGANON (NL) 2007-06-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110136789-A1 C-MET PROTEIN KINASE INHIBITORS MET, PRKCH, ABL1 HRH3 3184/4885GPR119 1367/4885CA1 3226/4885
US-11958837-B2 Quinazolinones as PARP14 inhibitors PARP14, PARP15, PARP11 HRH3 1961/4885GPR119 3964/4885CA1 4844/4885
US-11008308-B2 Quinazolinones as PARP14 inhibitors PARP14, PARP15, PARP11 HRH3 1961/4885GPR119 3964/4885CA1 4844/4885
US-20230018702-A1 QUINAZOLINONES AS PARP14 INHIBITORS PARP14, PARP15, PARP11 HRH3 1961/4885GPR119 3964/4885CA1 4844/4885
US-11981667-B2 Sulfonamide carboxamide compounds NLRP3, NOD1, PYCARD HRH3 2240/4885GPR119 24/4885CA1 2817/4885
US-20160332963-A1 12-EPI PLEUROMUTILINS MLN, TCF12, PLEC HRH3 3275/4885GPR119 3518/4885CA1 4316/4885
US-20230037255-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS NLRP3, NOD1, NLRP1 HRH3 2320/4885GPR119 13/4885CA1 2915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.